CO2017005201A2 - Ácido benzóico, derivados de ácido benzóico y conjugados heteroarilcarboxílico de la oxicodona - Google Patents

Ácido benzóico, derivados de ácido benzóico y conjugados heteroarilcarboxílico de la oxicodona

Info

Publication number
CO2017005201A2
CO2017005201A2 CONC2017/0005201A CO2017005201A CO2017005201A2 CO 2017005201 A2 CO2017005201 A2 CO 2017005201A2 CO 2017005201 A CO2017005201 A CO 2017005201A CO 2017005201 A2 CO2017005201 A2 CO 2017005201A2
Authority
CO
Colombia
Prior art keywords
oxycodone
benzoic acid
conjugates
heteroarylcarboxylic
acid derivatives
Prior art date
Application number
CONC2017/0005201A
Other languages
English (en)
Inventor
Travis Mickle
Sven Guenther
Sanjib Bera
Bindu Bera
Jaroslaw Kanski
Andrea K Martin
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Inc filed Critical Kempharm Inc
Publication of CO2017005201A2 publication Critical patent/CO2017005201A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04Salts; Organic complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La a tecnología actualmente descrita proporciona composiciones que comprenden ácidos arilcarboxílicos y, por ejemplo, AINES, químicamente conjugados a la oxicodona (4,5-α-epoxi-14-hidroxi-17-metilmorfinan-6-ona) para formar nuevos profármacos/composiciones de la oxicodona, incluyendo benzoatos, salicilatos, propionatos, fenamatos y acetatos, que tienen un menor potencial de abuso de la oxicodona. La presente tecnología también proporciona métodos para el tratamiento de pacientes, kits farmacéuticos y métodos para sintetizar conjugados de la presente tecnología.
CONC2017/0005201A 2014-11-25 2017-05-25 Ácido benzóico, derivados de ácido benzóico y conjugados heteroarilcarboxílico de la oxicodona CO2017005201A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084216P 2014-11-25 2014-11-25
US201462084246P 2014-11-25 2014-11-25
PCT/US2015/062637 WO2016086113A1 (en) 2014-11-25 2015-11-25 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone

Publications (1)

Publication Number Publication Date
CO2017005201A2 true CO2017005201A2 (es) 2017-08-31

Family

ID=56075034

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0005201A CO2017005201A2 (es) 2014-11-25 2017-05-25 Ácido benzóico, derivados de ácido benzóico y conjugados heteroarilcarboxílico de la oxicodona

Country Status (18)

Country Link
US (3) US9850252B2 (es)
EP (1) EP3223819A4 (es)
JP (2) JP6400848B2 (es)
KR (2) KR20190049944A (es)
CN (1) CN106999486A (es)
AU (1) AU2015353502B2 (es)
BR (1) BR112017011069A2 (es)
CA (1) CA2967424C (es)
CL (1) CL2017001353A1 (es)
CO (1) CO2017005201A2 (es)
IL (1) IL252470B (es)
MX (1) MX2017006520A (es)
NZ (1) NZ731591A (es)
PH (1) PH12017500963A1 (es)
RU (1) RU2683317C2 (es)
SG (1) SG11201704178UA (es)
WO (1) WO2016086113A1 (es)
ZA (1) ZA201703154B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
NZ731591A (en) 2014-11-25 2018-06-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone
WO2018071879A1 (en) * 2016-10-14 2018-04-19 Kempharm, Inc. Immediate-release abuse deterrent compositions or medicaments for treating pain, add, adhd and other syndromes or disorders
WO2019018638A1 (en) * 2017-07-20 2019-01-24 Suzhou Runxindatai Pharmaceutics Ltd Co. PRODRUGS OF EXTENDED RELEASE OPIOID OPIOIDS RESISTANT TO ABUSE
EP3755704A1 (en) * 2018-02-23 2020-12-30 Rhodes Technologies Inc. Novel opioid compounds and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB320749A (es)
US1731152A (en) 1925-10-27 1929-10-08 Firm C H Boehringer Sohn Process for the manufacture of derivatives of dihydrocodeinone or its substitution products
AT229496B (de) 1961-03-08 1963-09-25 Lannacher Heilmittel Verfahren zur Darstellung des neuen Nicotinsäureesters des Dihydrohydroxycodeinons
US4668685A (en) 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
SE9003665D0 (sv) 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
GB9423542D0 (en) 1994-11-22 1995-01-11 Marples Brian A Pharmaceutical compounds
US5869669A (en) * 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
IL150929A0 (en) 2000-01-28 2003-06-24 Rohm & Haas Pharmaceutical compounds comprising a pharmaceutically active moiety and a moiety comprising a substituent that enhances its properties
KR20040014544A (ko) 2001-06-05 2004-02-14 컨트롤 딜리버리 시스템즈 인코포레이티드 서방 진통제 화합물
US7375082B2 (en) 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
CA2477004C (en) 2002-02-22 2011-05-10 Thomas Piccariello Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
US20040058946A1 (en) 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
TW200500067A (en) 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
JP2006520392A (ja) * 2003-03-13 2006-09-07 コントロールド・ケミカルズ・インコーポレーテッド 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法
EP1782834A3 (en) * 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
EP1675555A4 (en) 2003-09-30 2011-03-09 Shire Llc PHARMACEUTICAL COMPOSITIONS FOR PREVENTING EXCESSIVE DOSE OR ABUSE
CA2874604A1 (en) 2003-10-03 2005-04-21 Elite Laboratories Inc. Extended release formulations of opioids and method of use thereof
US20050203115A1 (en) * 2004-03-10 2005-09-15 Sancilio Frederick D. Narcotic-NSAID ion pairs
RU2365580C2 (ru) 2004-06-04 2009-08-27 Ксенопорт, Инк. Пролекарства леводопа, композиции на их основе и их применения
US7348430B2 (en) 2005-01-21 2008-03-25 Acura Pharmaceuticals, Inc. Production of opioid analgesics
AU2007238858A1 (en) * 2006-04-10 2007-10-25 Shire Llc Mono and di-substituted oxycodone compounds and compositions
CA2653741C (en) 2006-05-26 2015-07-07 Thomas E. Jenkins Controlled release of phenolic opioids
US20080090771A1 (en) 2006-10-06 2008-04-17 Shire Llc Abuse-resistant hydrocodone compounds, compositions and methods of using the same
ES2569655T3 (es) 2007-12-17 2016-05-12 Mallinckrodt Llc Procedimientos para la producción de compuestos de (+)-'nal' morfinano
EP2448408A4 (en) * 2009-07-02 2015-06-03 Kempharm Inc CONJUGATES OF PHENYLETHANOIC ACID, PHENYLPROPANOIC ACID AND PHENYLPROPENOIC ACID AND HYDROCODONE PRODRUGS, METHODS OF MAKING AND USING THEM
UA102916C2 (uk) * 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US8623888B2 (en) 2009-07-15 2014-01-07 Mallinckrodt Llc 3-oxy-hydromorphone derivatives
ES2584634T3 (es) * 2011-01-11 2016-09-28 Signature Therapeutics, Inc. Composiciones que comprenden un profármaco de oxicodona escindible enzimáticamente
JP5769889B2 (ja) * 2011-10-26 2015-08-26 ケムファーム・インコーポレーテッド ヒドロモルホンの安息香酸、安息香酸誘導体及びヘテロアリールカルボン酸結合体、そのプロドラッグ、製造法及び使用
NZ731591A (en) 2014-11-25 2018-06-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone

Also Published As

Publication number Publication date
JP6400848B2 (ja) 2018-10-03
KR101976101B1 (ko) 2019-05-09
AU2015353502A1 (en) 2017-05-25
RU2017122144A (ru) 2018-12-26
NZ731591A (en) 2018-06-29
MX2017006520A (es) 2017-08-09
KR20170094249A (ko) 2017-08-17
US20180065975A1 (en) 2018-03-08
RU2017122144A3 (es) 2018-12-26
EP3223819A4 (en) 2018-04-25
US10144740B2 (en) 2018-12-04
SG11201704178UA (en) 2017-06-29
ZA201703154B (en) 2019-03-27
CL2017001353A1 (es) 2018-01-05
IL252470B (en) 2019-08-29
WO2016086113A1 (en) 2016-06-02
PH12017500963A1 (en) 2017-10-18
JP2018199719A (ja) 2018-12-20
CA2967424A1 (en) 2016-06-02
RU2683317C2 (ru) 2019-03-28
BR112017011069A2 (pt) 2018-07-10
US20190048018A1 (en) 2019-02-14
EP3223819A1 (en) 2017-10-04
US9850252B2 (en) 2017-12-26
CA2967424C (en) 2023-05-02
US10544153B2 (en) 2020-01-28
JP2017535593A (ja) 2017-11-30
IL252470A0 (en) 2017-07-31
AU2015353502B2 (en) 2018-09-27
CN106999486A (zh) 2017-08-01
KR20190049944A (ko) 2019-05-09
US20160168160A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
CO2017005201A2 (es) Ácido benzóico, derivados de ácido benzóico y conjugados heteroarilcarboxílico de la oxicodona
CU20110246A7 (es) Ácido benzoico, derivados de ácido benzoico y conjugados de ácido heteroaril carboxílico de hidrocodona, profármacos, métodos para elaborar y utilizar los mismos
BR112015022047A2 (pt) métodos para tratar câncer de bexiga
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CO6771409A2 (es) Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
BR112014010099A2 (pt) composição de pró-fármacos e uso de um conjugado
BR112015021524A2 (pt) derivados de sulfonil quinolina e usos dos mesmos
NI201500115A (es) Estra-1,3,5(10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
WO2015104292A3 (en) Compounds for use in treating or preventing cancerous diseases
MX378007B (es) Derivados de biarilo como agonistas de gpr120.
MX2015016971A (es) Formulacion que comprende un agente hipolipidemico.
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
BR112015029504A2 (pt) inibidores quinase
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
CO2017005203A2 (es) Acido benzoico, derivados de acido benzoico y conjugados de acido carboxilico de heteroarilo de oximorfona, profarmacos, metodos de fabricacion y uso de los mismos
BR112015022571A2 (pt) método de tratamento de esteatose hepática
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
AR095353A1 (es) Compuesto
BR112016006826A2 (pt) composição de spray tópico de halobetasol sem propelente, sistema de distribuição para a administração da composição de spray tópico, processo para a preparação da composição de spray tópico e método para o tratamento de condições de pele tópica
MX375468B (es) Amidas de acidos grasos para la prevencion y/o tratamiento de la esteatohepatitis.
MX369245B (es) Conjungados de nitrooxi-cromeno liberadores de oxido nitrico.